Machine Learning Predicts Noncalcified Coronary Burden in Psoriasis
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
Dyslipidemia
Setmelanotide Receives Orphan Drug Status for Alström Syndrome
The FDA has granted Orphan Drug designation to setmelanotide (Rhythm Pharmaceuticals) for the treatment of Alström Syndrome.
Relationship Between Arterial Stiffness and Depression Mediated by Metabolic Syndrome, Inflammation
Metabolic syndrome, including hypertension, obesity, dyslipidemia, and hyperglycemia, promote arterial stiffness, which has been linked to depression.
Detecting and Predicting Progression of Subclinical Vascular Damage in PLWHIV
While current cardiovascular risk scores can identify subclinical vascular damage in people living with HIV, they fail to predict progression of such damage.
Collaboration Between Medical Specialty Societies and Charitable Clinics Improves Health of Vulnerable Patient Groups
An ACC initiative in North Carolina aims to provide uninsured cardiac patients with heart medications free of charge.
Alirocumab Treatment for Autosomal Dominant Hypercholesterolemia
Treatment with alirocumab was found to be associated with clinically meaningful long-term reductions in low-density lipoprotein cholesterol (LDL-C) in patients with autosomal dominant hypercholesterolemia and elevated LDL-C treated with lipid-lowering therapy.
Consumption of Sugar-Sweetened Beverages Negatively Alters Lipid Profile Over Time
Consumption of sugar-sweetened beverages is associated with adverse changes in lipid profiles.
FDA Approves Bempedoic Acid, Ezetimibe Combination Therapy for LDL-C Lowering
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
Effects of Hypertriglyceridemia on Lipoprotein Function in Familial Combined Hyperlipidemia
Patients with familial combined hyperlipidemia may have more severe pro-atherogenic changes in the presence vs absence of hypertriglyceridemia.
Effects of BMI on Outcomes of Intensive LDL-C-Lowering Therapy
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
Next post in Cardiovascular and Metabolic Disorders
